EP Patent

EP3834889A1 — Treating myelomas

Assigned to Mayo Foundation for Medical Education and Research · Expires 2021-06-16 · 5y expired

What this patent protects

This document provides methods and materials related to treating myelomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD38 polypeptide antibody complexes) to treat mye…

USPTO Abstract

This document provides methods and materials related to treating myelomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD38 polypeptide antibody complexes) to treat myelomas are provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP3834889A1
Jurisdiction
EP
Classification
—
Expires
2021-06-16
Drug substance claim
No
Drug product claim
No
Assignee
Mayo Foundation for Medical Education and Research
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.